Lung Transplantation for Interstitial Lung Disease

Overview

Journal Eur Respir Rev

Specialty Pulmonary Medicine

Date 2021 Aug 5

PMID 34348979

Citations 23

Authors

Siddhartha G Kapnadak

Ganesh Raghu

Affiliations

Soon will be listed here.

Abstract

Lung transplantation (LTx) can be a life-extending treatment option for patients with advanced and/or progressive fibrotic interstitial lung disease (ILD), especially idiopathic pulmonary fibrosis (IPF), fibrotic hypersensitivity pneumonitis, sarcoidosis and connective tissue disease-associated ILD. IPF is now the most common indication for LTx worldwide. Several unique features in patients with ILD can impact optimal timing of referral or listing for LTx, pre- or post-transplant risks, candidacy and post-transplant management. As the epidemiology of LTx and community practices have evolved, recent literature describes outcomes and approaches in higher-risk candidates. In this review, we discuss the unique and important clinical findings, course, monitoring and management of patients with IPF and other progressive fibrotic ILDs during pre-LTx evaluation and up to the day of transplantation; the need for co-management with clinical experts in ILD and LTx is emphasised. Some post-LTx complications are unique in these patient cohorts, which require prompt detection and appropriate management by experts in multiple disciplines familiar with telomere biology disorders and infectious, haematological, oncological and cardiac complications to enhance the likelihood of improved outcomes and survival of LTx recipients with IPF and other ILDs.

Citing Articles

Diagnosis, screening, and follow-up of patients with familial interstitial lung disease: Results from an international survey.

Moen E, Prior T, Kreuter M, Wuyts W, Molina-Molina M, Wijsenbeek M BMC Pulm Med. 2025; 25(1):59.

PMID: 39901224 PMC: 11792556. DOI: 10.1186/s12890-025-03532-0.

Gastrointestinal cancer incidence after lung transplantation in sarcoidosis patients.

Saeed G, Sanders T, Tumin D, Obi O, Oghoghorie S, Ali H Ann Gastroenterol. 2025; 38(1):80-84.

PMID: 39802287 PMC: 11724385. DOI: 10.20524/aog.2024.0932.

Diagnostic and prognostic implications of family history of fibrotic interstitial lung diseases.

Duminy-Luppi D, Alcaide-Aldeano A, Planas-Cerezales L, Bermudo G, Vicens-Zygmunt V, Luburich P Respir Res. 2024; 25(1):433.

PMID: 39695595 PMC: 11656921. DOI: 10.1186/s12931-024-03063-y.

Patient-centered care in pulmonary fibrosis: access, anticipate, and act.

Hofman D, Magri T, Moor C, Richeldi L, Wijsenbeek M, Waseda Y Respir Res. 2024; 25(1):395.

PMID: 39487454 PMC: 11531140. DOI: 10.1186/s12931-024-02997-7.

Advances in the identification and management of progressive pulmonary fibrosis: perspective from Chinese experts.

Huang H, Wang Q, Xu Z Ther Adv Respir Dis. 2024; 18:17534666241288417.

PMID: 39415340 PMC: 11489892. DOI: 10.1177/17534666241288417.

References

Meyer K, Raghu G, Verleden G, Corris P, Aurora P, Wilson K . An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J. 2014; 44(6):1479-503. DOI: 10.1183/09031936.00107514. View

Biscotti M, Gannon W, Agerstrand C, Abrams D, Sonett J, Brodie D . Awake Extracorporeal Membrane Oxygenation as Bridge to Lung Transplantation: A 9-Year Experience. Ann Thorac Surg. 2017; 104(2):412-419. DOI: 10.1016/j.athoracsur.2016.11.056. View

Caminati A, Lonati C, Cassandro R, Elia D, Pelosi G, Torre O . Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue. Eur Respir Rev. 2019; 28(153). PMC: 9488913. DOI: 10.1183/16000617.0044-2019. View

Vadnerkar A, Toyoda Y, Crespo M, Pilewski J, Mitsani D, Kwak E . Age-specific complications among lung transplant recipients 60 years and older. J Heart Lung Transplant. 2010; 30(3):273-81. DOI: 10.1016/j.healun.2010.08.032. View

Villavicencio M, Axtell A, Osho A, Astor T, Roy N, Melnitchouk S . Single- Versus Double-Lung Transplantation in Pulmonary Fibrosis: Impact of Age and Pulmonary Hypertension. Ann Thorac Surg. 2018; 106(3):856-863. DOI: 10.1016/j.athoracsur.2018.04.060. View

Wajda N, Zhu Z, Jandarov R, Dilling D, Gupta N . Clinical outcomes and survival following lung transplantation in patients with pulmonary Langerhans cell histiocytosis. Respirology. 2019; 25(6):644-650. PMC: 8643712. DOI: 10.1111/resp.13671. View

TOBIN R, Pope 2nd C, Pellegrini C, Emond M, Sillery J, Raghu G . Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998; 158(6):1804-8. DOI: 10.1164/ajrccm.158.6.9804105. View

Cantu 3rd E, Appel 3rd J, Hartwig M, Woreta H, Green C, Messier R . J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg. 2004; 78(4):1142-51. DOI: 10.1016/j.athoracsur.2004.04.044. View

Li M, Mathur S, Chowdhury N, Helm D, Singer L . Pulmonary rehabilitation in lung transplant candidates. J Heart Lung Transplant. 2013; 32(6):626-32. DOI: 10.1016/j.healun.2013.04.002. View

10.

Yoon H, Kim T, Seo J, Lee S, Lim S, Lee H . Effects of emphysema on physiological and prognostic characteristics of lung function in idiopathic pulmonary fibrosis. Respirology. 2018; 24(1):55-62. DOI: 10.1111/resp.13387. View

11.

Whelan T, Dunitz J, Kelly R, Edwards L, Herrington C, Hertz M . Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant. 2005; 24(9):1269-74. DOI: 10.1016/j.healun.2004.10.014. View

12.

Nathan S, Albera C, Bradford W, Costabel U, Glaspole I, Glassberg M . Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2016; 5(1):33-41. DOI: 10.1016/S2213-2600(16)30326-5. View

13.

Chambers D, Cherikh W, Harhay M, Hayes Jr D, Hsich E, Khush K . The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart-lung transplantation Report-2019; Focus theme: Donor and recipient size match. J Heart Lung Transplant. 2019; 38(10):1042-1055. PMC: 6816340. DOI: 10.1016/j.healun.2019.08.001. View

14.

Inoue Y, Kaner R, Guiot J, Maher T, Tomassetti S, Moiseev S . Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype. Chest. 2020; 158(2):646-659. DOI: 10.1016/j.chest.2020.03.037. View

15.

Singer J, Diamond J, Gries C, McDonnough J, Blanc P, Shah R . Frailty Phenotypes, Disability, and Outcomes in Adult Candidates for Lung Transplantation. Am J Respir Crit Care Med. 2015; 192(11):1325-34. PMC: 4731703. DOI: 10.1164/rccm.201506-1150OC. View

16.

McAnally K, Valentine V, LaPlace S, McFadden P, Seoane L, Taylor D . Effect of pre-transplantation prednisone on survival after lung transplantation. J Heart Lung Transplant. 2006; 25(1):67-74. DOI: 10.1016/j.healun.2005.07.012. View

17.

Dotan Y, Vaidy A, Shapiro W, Zhao H, Dass C, Toyoda Y . Effect of Acute Exacerbation of Idiopathic Pulmonary Fibrosis on Lung Transplantation Outcome. Chest. 2018; 154(4):818-826. DOI: 10.1016/j.chest.2018.06.027. View

18.

Borie R, Kannengiesser C, Hirschi S, Le Pavec J, Mal H, Bergot E . Severe hematologic complications after lung transplantation in patients with telomerase complex mutations. J Heart Lung Transplant. 2015; 34(4):538-46. DOI: 10.1016/j.healun.2014.11.010. View

19.

Sottile P, Iturbe D, Katsumoto T, Connolly M, Collard H, Leard L . Outcomes in systemic sclerosis-related lung disease after lung transplantation. Transplantation. 2013; 95(7):975-80. PMC: 3616420. DOI: 10.1097/TP.0b013e3182845f23. View

20.

King Jr T, Bradford W, Castro-Bernardini S, Fagan E, Glaspole I, Glassberg M . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2083-92. DOI: 10.1056/NEJMoa1402582. View